US President Looks To Double The Drugs For Price Negotiation
President Joe Biden is looking to double the number of medicines that Medicare can help negotiate rates for and thereby enable the government to...
Default Eligibility Results In Better Clinical Trial Nods
A new approach that has been created at the Medical University of South Carolina that specifically aims at enhancing clinical trial eligibility has shown...
Novel Purification Means For Protein Drug Manufacturing
In a recent study, researchers at the Massachusetts Institute of Technology (MIT) have come up with a new purification approach to reduce the cost...
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
One of the most important trade fairs in the pharmaceutical industry will soon be taking place in Japan as it sees a huge resurgence...
Duchenne Muscular Dystrophy-Cancer Genetic Link Discovered
Scientists from the University of Portsmouth have settled on a novel genetic link between Duchenne muscular dystrophy and cancer.
Duchenne muscular dystrophy, which happens...
Animal Testing Could See An End With An Artificial Model
Uppsala University researchers have created an artificial blood-brain barrier model that can be used to assess the efficacy of anti-body-based medicines while reducing animal...
Bioavailability Enhancement Market Projects CAGR of 11%
Since more biopharmaceutics classification system- BCS II as well as BCS IV molecules are being evaluated in the early stages of development, one of...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...